Global Proto Oncogene Market & Clinical Pipeline Insight 2024

  • ID: 4460751
  • Drug Pipelines
  • Region: Global
  • 440 Pages
  • Kuick Research
1 of 5

FEATURED COMPANIES

  • ARIAD Pharmaceuticals
  • Bayer Healthcare
  • ChemGenex Pharmaceuticals
  • Eisai Pharmaceuticals
  • GlaxoSmithKline
  • Onyx Pharmaceuticals
  • MORE

“Global Proto Oncogene Market & Clinical Pipeline Insight 2024” report gives comprehensive insight on ongoing clinical and non-clinical parameters involved in the development of global proto oncogene market in recent years.  Currently there are 19 proto oncogene inhibitors drugs commercially available in the market and 166 are in clinical pipeline in various developmental phases. 

“Global Proto Oncogene Market & Clinical Pipeline Insight 2024” report highlights:

  • Oncogenes as Therapeutic Targets for Treatment
  • Market Analysis of Proto Oncogene Therapeutic Drugs
  • Dosage & Price Analysis of Drugs
  • Patent & Approval Year Insight
  • Proto Oncogene Inhibitors Clinical Pipeline by Company, Indication & Phase
  • Marketed Proto Oncogene Inhibitors Clinical Insight by Company & Indication

Cancer has been designated as a complex genetic and cellular disease as it affects growth of cells due to sudden alterations in the genes. However, most of the conventional anti-cancer therapies developed for treating cancer were directed towards killing the tumor cells and were ineffective in inhibiting the cancer-causing transformations that occur in genes of normal cells. Nevertheless several modern cancer therapies have been recently developed including targeted drugs and immunotherapeutics. Although these regimens interrupt the expression of cancer genes but either by affecting the gene indirectly or with lesser efficacy which further leads to ineffective treatment of cancer. 

Proto-oncogene Inhibitors are recently developed class of anti-cancer therapeutics possessing a unique mode of action as they directly inhibit the activation of cancer causing genes. Proto-oncogenes are inactivated form of cancerous genes which function normally until they’re activated by several factors or cellular mechanisms.  When such factors activate proto-oncogene, then it gets transformed to form an oncogene which induces cancer development. Proto-oncogene Inhibitors are involved in direct inhibition of this transformation from inactive proto-oncogene to active oncogene and restricting cancer growth.

Global Cancer Therapy Market has been flourished with a wide range of proto-oncogene inhibitors in the past decade and has acquired a larger portion of the market. Furthermore, presence of a wide variety of proto-oncogenes in a human body has provided several targets for developing unique proto-oncogene inhibitors. These facts clearly indicate that proto-oncogene inhibitors is a major class of anti-cancer therapeutics comprising a wide variety of inhibitors based on different proteins and mechanisms which are affected by particular oncogenes.

Proto-oncogene Inhibitors represent a well-established global market as it possess close to 20 commercialized products amongst which more than 5 are in the list of top selling anti-cancer drugs. For instance, Imatinib is one of the proto-oncogene inhibitors which have collected more than US$ 10 Billion in past four to five years. Additionally, another proto-oncogene inhibitor namely Sutent has generated US$ 2 Billion in past three years.

Moreover more than 20 drugs are in the later phases of clinical pipeline and are expected to be approved in the coming four to five years. Furthermore, Biosimilars of highly popular proto-oncogene inhibitors have already been commercialized and have gained an excellent response in the market. Patent expiration of other popular proto-oncogene inhibitors will provide opportunities for the development and commercialization of more biosimilars.

Nonetheless, as proto-oncogene inhibitors are a larger class of anti-cancer therapeutics, development and advancement in genomic studies have successfully led to identification of more targets to form proto-oncogene inhibitors. Due to this reason, proto-oncogene inhibitors market is expected to expand with the entrance of more sub-classes of drugs under this class. This indicates that although proto-oncogene inhibitor market is well-established yet highly opportunistic for the scientific community as well as the pharmaceutical market.

Initially approved products in the proto-oncogene inhibitor market such as Imatinib has stayed in the market since 2001 and has continuously generated high revenues; even in the presence of highly competitive market with successive approvals of new proto-oncogene Inhibitors. Such examples are appropriate examples suggest that Global proto-oncogene market will continue to grow exponentially even in a highly competitive market space.

Proto-oncogene inhibitors are actively being supported by large scale as well as small scale pharmaceutical companies from different regions of the world. Key market players are Dexa Medica, Eisai Pharmaceuticals, Exelixis, Pfizer, Novartis, AstraZeneca and many more. Additionally, investments and funding from private as well as public sector is further an encouraging factor for the research laboratories and science institutes to develop unique proto-oncogene inhibitors indicating that this market is expected to grow at an unusually high growth rate in the coming future.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ARIAD Pharmaceuticals
  • Bayer Healthcare
  • ChemGenex Pharmaceuticals
  • Eisai Pharmaceuticals
  • GlaxoSmithKline
  • Onyx Pharmaceuticals
  • MORE

1. Introduction to Proto Oncogenes
1.1 Overview
1.2 Discovery of Transmissible Cancer Gene
1.3 Products of Oncogenes

2. Activation of Proto Oncogene to Oncogenes
2.1 From Proto Oncogenes to Oncogenes
2.1.1 Gene Amplification
2.1.2 Chromosomal Translocation
2.1.3 Mutations
2.2 Hallmarks of Cancer

3. Oncogenes as Therapeutic Targets for Treatment
3.1 ERBB2 as a Target for Breast Cancer Therapy
3.2 EGFR as a Target for Colorectal Cancer Therapy
3.3 VEGF as a Target for Non-Small Cell Lung Cancer
3.4 PDGFR as a Target for Renal Cell Carcinoma

4. Prognostic & Predictive Role of Oncogenes
4.1 HER2
4.2 BRAF V600E
4.3 BCL-2
4.4 SRC

5. Market Analysis of Proto Oncogene Therapeutic Drugs
5.1 Axitinib (Inlyta)
5.2 Ponatinib (Iclusig)
5.3 Imatinib (Gleevec)
5.4 Sunitinib (Sutent)
5.5 Pazopanib (Votrient)
5.6 Dabrafenib (Tafinlar)
5.7 Vandetanib (Caprelsa)
5.8 Vemurafenib (Zelboraf)
5.9 Cabozantinib (Cabometyx & Cometriq)
5.10 Sorafenib (Nexavar)

6. Market Introduction of Proto Oncogenes
6.1 Overview
6.2 Global Sales of Proto-Oncogene Drugs
6.3 Global Proto Oncogene Protein Inhibitors Pipeline Overview

7. Global Proto Oncogene Market Dynamics
7.1 Favorable Market Parameters
7.2 Commercialization Challenges

8. Future Perspective of Proto Oncogene Market

9. Global Proto-Oncogene Protein Inhibitors Clinical Pipeline by Company, Indication & Phase
9.1 Research
9.2 Preclinical
9.3 Clinical
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-III
9.8 Preregistration
9.9 Registered

10. Marketed Global Proto-Oncogene Protein Inhibitors Clinical Insight by Company & Indication
10.1 Axitinib (Inlyta)
10.2 Ponatinib (Iclusig)
10.3 Imatinib (Gleevec, Glivec & Ruvise)
10.4 Lenvatinib (Kisplyx & Lenvima)
10.5 Sunitinib (Sutent)
10.6 Pazopanib (Votrient)
10.7 Dabrafenib (Tafinlar)
10.8 Vandetanib (Caprelsa, Zactima & Zictifa)
10.9 Vemurafenib (Zelboraf)
10.10 Cabozantinib (Cabometyx & Cometriq)
10.11 Nilotinib (Tasigna)
10.12 Regorafenib (Stivarga)
10.13 Dasatinib (Sprycel)
10.14 Sorafenib (Nexavar)
10.15 Crizotinib (Xalkori)
10.16 Apatinib
10.17 Omacetaxine Mepesuccinate (Synribo)
10.18 Imatinib - Pharm-Sintez (Imatib)
10.19 Phaleria Macrocarpa extract (Phalecarps)

11. Competitive Landscape
11.1 ARIAD Pharmaceuticals
11.2 AstraZeneca
11.3 Bayer Healthcare
11.4 Bristol-Myers Squibb
11.5 ChemGenex Pharmaceuticals
11.6 Dexa Medica
11.7 Eisai Pharmaceuticals
11.8 Exelixis
11.9 GlaxoSmithKline
11.10 Novartis
11.11 Onyx Pharmaceuticals
11.12 Plexxikon
11.13 Pfizer

List of Figures
Figure 1-1: Historical Development of Oncogenes in Various Cancer Cell Lines
Figure 1-2: Organization of the Proto Oncogene Products
Figure 2-1: Activation Methods of Oncogenes from Proto Oncogenes
Figure 2-2: Gene Amplification Step in the Conversion of Proto Oncogenes to Oncogenes
Figure 2-3: Chromosomal Translocation for the Activation Oncogene from Proto Oncogene
Figure 2-4: Classification of the Hallmarks of Cancer
Figure 3-1: Role of VEGF as a Target to Non-Small Cell Lung Cancer
Figure 3-2: PDGFR Target for the Treatment of Renal Cell Carcinoma
Figure 5-1: Axitinib- Patent Approval & Expiration Year in US
Figure 5-2: Axitinib- Patent Approval & Expiration Year in Europe
Figure 5-3: Axitinib Dosage Analysis (mg/Day)
Figure 5-4: Available Concentrations of Axitinib Oral Tablet (mg)
Figure 5-5: Inlyta- Price Analysis by Concentration (US$/Unit), 2018
Figure 5-6: Axitinib Price Analysis US$/Packet), 2018
Figure 5-7: Axitinib Treatment Cost (US$/Cycle), 2017
Figure 5-8: Ponatinib- Patent Approval Year & Expiration Year in US
Figure 5-9: Ponatinib- Patent Approval Year & Expiration Year in Europe
Figure 5-10: Iclusig Dosage Analysis (mg/Day)
Figure 5-11: Available Concentrations of Iclusig Oral Tablet Drug, mg
Figure 5-12: Iclusig- Price Analysis (US$), 2017
Figure 5-13: Imatinib- Patent Approval Year & Patent Expiration Year in US
Figure 5-14: Imatinib- Patent Approval Year & Patent Expiration Year in Europe
Figure 5-15: Imatinib Price Analysis by Concentration (US$/Unit), 2017
Figure 5-16: Imatinib Price Analysis by Concentration (US$/Packet), 2017
Figure 5-17: Sunitinib- Patent Approval Year & Expiration Year in US
Figure 5-18: Sunitinib- Patent Approval Year & Expiration Year in Europe
Figure 5-19: Available Concentrations of Sunitinib Drug, mg
Figure 5-20: Sutent Capsule Price by Concentration (US$/Unit), 2017
Figure 5-21: Sunitinib- Price Analysis by Concentration (US$/Packet), 2017
Figure 5-22: Pazopanib- Patent Approval Year & Patent Expiration Year in US
Figure 5-23: Pazopanib- Patent Approval Year & Patent Expiration Year in Europe
Figure 5-24: Pazopanib Dosage Analysis (mg/Day)
Figure 5-25: Pazopanib Price Analysis by Quantity (US$), 2017
Figure 5-26: Dabrafenib- Patent Approval & Expiration Year in US
Figure 5-27: Dabrafenib- Patent Approval & Expiration Year in Europe
Figure 5-28: Dabrafenib Dosage Analysis (mg/Day)
Figure 5-29: Available Concentration of Dabrafenib Drug, mg
Figure 5-30: Dabrafenib Price Analysis by Concentration (US$/Unit), 2017
Figure 5-31: Tafinlar Capsule Average Price Analysis by Concentration (US$/120 Capsules), 2017
Figure 5-32: Vandetanib- Patent Approval & Expiration Year in US
Figure 5-33: Vandetanib- Patent Approval & Expiration Year in Europe
Figure 5-34: Vandetanib Dosage Analysis (mg/Day)
Figure 5-35: Available Concentrations of Vandetanib Drug, mg
Figure 5-36: Vandetanib Price Analysis (US$/Unit), 2017
Figure 5-37: Vandetanib- Drug Cost (US$) in Concentration of 100 mg & 300 mg for 30 Tablets, 2017
Figure 5-38: Vemurafenib- Patent Approval Year & Expiration Year in US & Europe
Figure 5-39: Vemurafenib- Patent Approval Year & Expiration Year in Europe
Figure 5-40: Vemurafenib Dosage Analysis (mg/Day)
Figure 5-41: Vemurafenib- Market Cost of Drug (US$) for 112 Tablets & Per Unit Cost, 2017
Figure 5-42: Cabozantinib- Patent Approval Year & Expiration Year in US
Figure 5-43: Cabozantinib- Patent Approval Year & Expiration Year in Europe
Figure 5-44: Cabozantinib Dosage Analysis (mg/Day)
Figure 5-45: Available Concentrations of Cabozantinib Oral Tablet, mg
Figure 5-46: Available Drug Concentrations of Cometriq Oral Capsule, mg
Figure 5-47: Cabozantinib- Drug Cost of 20mg Concentration (US$) for 30 Tablets & Per Unit Dose, 2017
Figure 5-48: Cost of Cometriq Capsules for the Supply of 50 Capsules of Different Concentrations, (US$)
Figure 5-49: Sorafenib- Patent Approval Year & Expiration Year in US
Figure 5-50: Sorafenib- Patent Approval Year & Expiration Year in Europe
Figure 5-51: Sorafenib- Drug Cost for 120 Tablets & Per Unit Dose (US$), 2017
Figure 6-1: Global- Axitinib Drug Sales (US$ Million), 2015 & 2016
Figure 6-2: Iclusig - Sales (US$ Million), 2015
Figure 6-3: Iclusig - Sales (US$), 2016 & 2017
Figure 6-4: Global- Sales Revenue of Sunitinib Drug (US$ Billion), 2015 & 2016
Figure 6-5: Global- Sales of Pazopanib Drug (US$ Million), 2015 & 2016
Figure 6-6: Global- Sales Revenue of Vemurafenib Drug (US$ Million), 2015 & 2016
Figure 6-7: Global- Sales of Imatinib (US$ Billion), 2014-2017
Figure 6-8: Global Sales of Dabrafenib Drug (US$ Million), 2015 & 2016
Figure 6-9: Global Sales Revenue of Sorafenib Drug (US$ Million), 2014-2016
Figure 6-10: Cabozantinib (Cabometyx & Cometriq) - Sales (US$ Million), 2016 & 2017*
Figure 6-11: Cabometyx & Cometriq - Sales (US$ Million), 2016 & 2017*
Figure 6-12: Global Proto Oncogene Protein Inhibitors Clinical Pipeline by Phase (%), 2017 till 2024
Figure 6-13: Global Proto-Oncogene Protein Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2024
Figure 7-1: Favorable Factors which Promote the Market Growth of Proto Oncogenes
Figure 7-2: Challenges to the Market Growth of Proto Oncogenes
Figure 8-1: Frontiers for the Inhibition of Cancer Development by Active Oncogenes

List of Tables
Table 3-1: Possible Ways to Overcome ErBb2 Mediated Chemoresistance
Table 3-2: Components of EGFR Signaling Pathway Important in Colorectal Cancer
Table 4-1: Role of Cancer Oncogene as Predictive & Prognostic Biomarker
Table 5-1: Imatinib Dosage for Various Indications (mg/Day & mg/m2/Day)
Table 5-2: Cost Effective Analysis of Imatinib Drug
Table 5-3: Clinical Efficacy Results of Sunitinib Drug in Cancer Treatment
Table 5-4: Clinical Efficacy Results of Pazopanib Drug in Cancer Treatment
Table 5-5: Clinical Effective Analysis of Dabrafenib Drug
Table 5-6: Clinical Effective Analysis of Vandetanib Drug
Table 5-7: Clinical Efficacy of Vemurafenib Drug in Cancer Treatment

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • ARIAD Pharmaceuticals
  • AstraZeneca
  • Bayer Healthcare
  • Bristol-Myers Squibb
  • ChemGenex Pharmaceuticals
  • Dexa Medica
  • Eisai Pharmaceuticals
  • Exelixis
  • GlaxoSmithKline
  • Novartis
  • Onyx Pharmaceuticals
  • Pfizer
  • Plexxikon
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll